Ra Capital Management, L.P. 89bio, Inc. Call Options Transaction History
Ra Capital Management, L.P.
- $4.58 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ETNB
# of Institutions
212Shares Held
162MCall Options Held
289KPut Options Held
1.6M-
Janus Henderson Group PLC London, X020.8MShares$188 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.2MShares$128 Million4.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.5MShares$85.9 Million3.31% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.24MShares$74.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$63.4 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $420M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...